文献速递中医内科中药与中成药合理使用

桂枝甘草汤通过抑制SERCA2a泛素化缓解异丙肾上腺素诱导的慢性心力衰竭机制研究

Mechanistic investigation of Guizhi Gancao decoction in alleviating isoproterenol-induced chronic heart failure via inhibition of sarcoplasmic/endoplasmic (SR/ER) reticulum Ca2+-ATPase 2a ubiquitination.
PubMed 文献 · J Ethnopharmacol · 2026-06-02

该研究在异丙肾上腺素诱导的C57BL/6小鼠慢性心力衰竭模型中探究桂枝甘草汤的治疗作用及机制。结果显示桂枝甘草汤改善心功能、减轻心肌肥厚与纤维化,机制涉及调节cAMP/PKA通路、抑制PKA-蛋白酶体结合、减少SERCA2a泛素化降解并保护钙瞬变。

要点

  • 桂枝甘草汤改善ISO诱导CHF小鼠的心功能与结构重构。
  • 机制涉及抑制PKA-蛋白酶体结合、减少SERCA2a泛素化降解。
  • 研究仅用单批次桂枝甘草汤,结论属初步需多批次验证。

核心结论

  • 桂枝甘草汤通过调节cAMP/PKA通路、抑制PKA-蛋白酶体相互作用并维持SERCA2a依赖的钙循环,缓解ISO诱导的慢性心力衰竭。
  • 桂枝甘草汤可能成为靶向UPS介导SERCA2a降解的CHF治疗候选药物,但研究为单批次药物,结论属初步。

研究设计与样本

  • 采用C57BL/6小鼠皮下注射异丙肾上腺素建立慢性心力衰竭模型。
  • 通过超声心动图、组织病理学(HE与Masson染色)及分子标志物(ANP、BNP)评价心功能与结构重构。
  • 采用血清代谢组学联合蛋白质印迹鉴定关键信号通路。
  • 采用免疫共沉淀与质谱探索蛋白-蛋白相互作用。
  • 通过分子对接与体外钙瞬变实验验证关键靶点的功能相关性。

主要发现

  • 桂枝甘草汤治疗显著改善ISO诱导的心功能障碍,表现为射血分数(EF)和缩短分数(FS)升高、左心室内径(LVIDs/d)减小。
  • 桂枝甘草汤减轻病理性心肌肥厚与纤维化,尤其在低剂量时明显,并下调ANP/BNP表达。
  • 代谢组学提示cAMP/PKA通路为关键靶点,桂枝甘草汤可逆转ISO引起的PKA调节亚基(RI-α/β)和催化亚基(α/β/γ)上调。
  • 桂枝甘草汤中5种活性成分(如4-羟基肉桂酸、18α-甘草次酸)与PKA具有强结合亲和力。
  • 免疫共沉淀-质谱显示PKA与蛋白酶体相关蛋白(Psma2、Psmb5、Ube2d3)相互作用,桂枝甘草汤抑制ISO增强的PKA-蛋白酶体结合并恢复UPS稳态。

临床怎么用

  • 桂枝甘草汤在ISO诱导CHF小鼠中改善心功能与结构重构,支持其作为CHF潜在治疗方剂的进一步研究。
  • 其作用机制与调节cAMP/PKA通路、抑制PKA-蛋白酶体结合及保护SERCA2a钙循环相关,为临床机制理解提供参考。

局限性

  • 研究仅使用单批次桂枝甘草汤,结论应视为初步,需跨多批次药材进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chronic heart failure (CHF) remains a leading cause of mortality globally, with limited therapeutic options targeting its underlying pathological mechanisms. Guizhi Gancao Decoction (GGD), a classic traditional Chinese medicine formula, has been used for centuries to treat cardiovascular diseases, but its molecular mechanisms in CHF remain elusive. AIM OF THE STUDY: This study aimed to investigate the therapeutic effects of GGD on isoproterenol (ISO)-induced CHF in mice and explore its underlying mechanisms, focusing on the cAMP/PKA signaling pathway, ubiquitin-proteasome system (UPS), and calcium handling. METHODS: A CHF model was established by subcutaneous injection of ISO in C57BL/6 mice. Cardiac function and structural remodeling were evaluated using echocardiography, histopathology (hematoxylin-eosin staining, Masson staining), and molecular markers (ANP, BNP). Serum metabolomics combined with western blotting was used to identify key signaling pathways. Co-immunoprecipitation (Co-IP) and mass spectrometry (MS) were employed to explore protein-protein interactions. Molecular docking and in vitro calcium transient assays validated the functional relevance of key targets. RESULTS: GGD treatment significantly improved ISO-induced cardiac dysfunction, as evidenced by increased ejection fraction (EF), fractional shortening (FS), and reduced left ventricular internal diameters (LVIDs/d). Pathological hypertrophy and fibrosis were attenuated by GGD, particularly at low doses, with downregulated ANP/BNP expression. Metabolomic profiling identified the cAMP/PKA pathway as a critical target, where GGD normalized ISO-induced upregulation of PKA regulatory (RI-α/β) and catalytic (α/β/γ) subunits. Five active ingredients in GGD (e.g., 4-hydroxy cinnamic acid, 18α-glycyrrhetinic acid) exhibited strong binding affinity to PKA. Co-IP-MS revealed PKA interaction with proteasome-related proteins (Psma2, Psmb5, Ube2d3), and GGD inhibited ISO-enhanced PKA-proteasome binding, restoring UPS homeostasis. Importantly, GGD reduced ubiquitin-mediated degradation of SERCA2a, preserved calcium transient dynamics, and improved cardiomyocyte contractility, an effect mimicked by the proteasome inhibitor MG132. CONCLUSION: GGD alleviates ISO-induced CHF by modulating the cAMP/PKA pathway, inhibiting PKA-proteasome interactions, and preserving SERCA2a-dependent calcium cycling. These findings highlight GGD as a promising therapeutic agent for CHF via targeting UPS-mediated SERCA2a degradation. However, because the present study was conducted using a single batch of GGD, the findings should be considered preliminary and require further validation across multiple batches of herbal materials.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li R, Yang S, Tang Y, et al. Mechanistic investigation of Guizhi Gancao decoction in alleviating isoproterenol-induced chronic heart failure via inhibition of sarcoplasmic/endoplasmic (SR/ER) reticulum Ca2+-ATPase 2a ubiquitination. J Ethnopharmacol. 2026. PMID: 42235714. doi:10.1016/j.jep.2026.121858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。